NCT03732794View on ClinicalTrials.gov

AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

NAActive, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

June 27, 2024

Study Completion Date

June 30, 2026

Conditions
Atrial Fibrillation (AF)Persistent Atrial FibrillationLongstanding Persistent Atrial Fibrillation
Interventions
DEVICE

AtriCure CryoICE & AtriClip LAA Exclusion

AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.

Trial Locations (15)

10029

Mount Sinai Icahn School of Medicine, New York

10065

NYP-Weill Cornell, New York

10075

Northwell Health Systems, New York

13203

St. Joseph Hospital Health Center, Syracuse

20912

Washington Adventist Hospital, Washington D.C.

21201

University Of Maryland, Baltimore

26506

West Virginia University, Morgantown

37205

St Thomas West Hospital, Nashville

46237

Franciscan Health, Indianapolis

47630

Deaconess Gateway Hospital, Newburgh

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic, Rochester

60611

Northwestern Medicine, Chicago

64111

St. Luke's Hospital, Kansas City

90095

UCLA Medical Center, Los Angeles

Sponsors

Lead Sponsor

AtriCure, Inc.
All Listed Sponsors
lead

AtriCure, Inc.

INDUSTRY